Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal

Home

Unité de Virologie et Immunologie Moléculaires

Protein macro-assembly and Prion diseases

As the Prion and other infectious amyloids belong to the no-conventional infectious agents, we developed a multidisciplinary approach which address the molecular basis of this type of pathology to finally allow to set up a rational drug design strategy.

Prion diseases are deadly infectious neurodegenerative diseases affecting human and other mammalian species. The etiology of prion disease differs from the conventional infectious diseases and leads to introduce the general concept of infectious amyloidosis.

Our main field of investigation address the molecular mechanism of structural information transference during mammalian prion replication and the neurotoxicity mechanisms of misfolded proteins.

Our investigations cover a broad panel of expertises: from physical-chemistry and drug design to the molecular characterisation of the prion propagation on transgenic mice and cell models.

We also intensively contribute to the development of new methodology and tools in the field of infectious proteins.

The most percussive results obtained by our group address major topics in prion field. We identified the minimal structural perturbation that ignites the replication process and established a relation between infectivity and size of PrPSc assemblies.

The accumulation of fundamental knowledge leads us to design ligand that inhibits the prion replication ex vivo. The characterization of the prion passage from animals to human was one of the important topics that we also addressed using transgenic mice.

Beside these results, our group intensively built gateways between prion disease and other amyloidosis as Alzheimer and type 1 Parkinson. As our group have a multidisciplinary approach, our perspective is to gain from fundamental research to go further in the etiology of infectious amyloidosis and rational drug design.